转移性肾细胞癌治疗的新视角：引言和历史概述。
New perspectives on the treatment of metastatic renal cell carcinoma: an introduction and historical overview.
机构信息
Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA.
出版信息
Oncologist. 2011;16 Suppl 2(Suppl 2):1-3. doi: 10.1634/theoncologist.2011-S2-01.
Abstract
The content of the supplement is summarized, including a review of the pathogenesis and diagnosis of renal cell carcinoma and the efficacy and safety of the currently available targeted therapies.
摘要
该补充剂的内容概述，包括肾细胞癌的发病机制和诊断的回顾，以及目前可用的靶向治疗的疗效和安全性。
相似文献
1
New perspectives on the treatment of metastatic renal cell carcinoma: an introduction and historical overview.转移性肾细胞癌治疗的新视角：引言和历史概述。
Oncologist. 2011;16 Suppl 2(Suppl 2):1-3. doi: 10.1634/theoncologist.2011-S2-01.
2
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.肾细胞癌：ESMO 诊断、治疗及随访临床实践指南
Ann Oncol. 2010 May;21 Suppl 5:v137-9. doi: 10.1093/annonc/mdq206.
3
NCCN clinical practice guidelines in oncology: kidney cancer.美国国立综合癌症网络（NCCN）肿瘤学临床实践指南：肾癌
J Natl Compr Canc Netw. 2009 Jun;7(6):618-30. doi: 10.6004/jnccn.2009.0043.
4
Renal cell carcinoma: what the surgeon and treating physician need to know.肾细胞癌：外科医生和治疗医生需要了解的内容。
AJR Am J Roentgenol. 2011 Jun;196(6):1255-62. doi: 10.2214/AJR.10.6249.
5
Kidney cancer. Clinical practice guidelines in oncology.肾癌。肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2006 Nov;4(10):1072-81. doi: 10.6004/jnccn.2006.0089.
6
Integrative tumor board: metastatic renal cell carcinoma: medical oncology (II).综合肿瘤病例讨论会：转移性肾细胞癌：医学肿瘤学（二）
Integr Cancer Ther. 2004 Mar;3(1):29-34. doi: 10.1177/1534735404262986.
7
Metastatic renal cell carcinoma: systemic treatment.转移性肾细胞癌：全身治疗
Acta Urol Belg. 1996 May;64(2):3-8.
8
Late recurrences of renal cell carcinoma at unusual sites: implications for patient management.
Clin Adv Hematol Oncol. 2012 Feb;10(2):126-8.
9
Integrative tumor board: metastatic renal cell carcinoma: medical oncology.综合肿瘤学讨论组：转移性肾细胞癌：医学肿瘤学
Integr Cancer Ther. 2004 Mar;3(1):26-9. doi: 10.1177/1534735403261846.
10
Targeted therapy for locally advanced renal cell carcinoma.局部进展性肾细胞癌的靶向治疗。
Target Oncol. 2010 Jun;5(2):113-8. doi: 10.1007/s11523-010-0147-4. Epub 2010 Jul 14.
引用本文的文献
1
A Resected Case of Simultaneous Gastric and Multiple Pancreatic Metastases of Renal Cell Carcinoma 11 Years After Nephrectomy.肾切除术后11年出现同时性胃和胰腺多发转移的肾细胞癌切除病例
Cureus. 2024 Sep 10;16(9):e69108. doi: 10.7759/cureus.69108. eCollection 2024 Sep.
2
FBLN5 as One Presumably Prognostic Gene Potentially Modulating Tumor Immune Microenvironment for Renal Clear Cell Carcinoma in Children and Young Adults.FBLN5作为一种可能的预后基因，可能调节儿童和年轻成人肾透明细胞癌的肿瘤免疫微环境。
Pharmgenomics Pers Med. 2024 Jan 19;17:27-40. doi: 10.2147/PGPM.S442803. eCollection 2024.
3
Trends in Initial Systemic Therapy for Elderly Patients with Metastatic Clear Cell Renal Cell Carcinoma.老年转移性透明细胞肾细胞癌患者初始系统治疗的趋势
Kidney Cancer. 2020 Sep 16;4(3):131-137. doi: 10.3233/KCA-200089.
4
Analysis of the concordance of 20 immunohistochemical tissue markers in metastasectomy lesions in patients with metastatic renal cell carcinoma: A retrospective study using tissue microarray.转移性肾细胞癌患者转移切除病灶中 20 种免疫组织化学组织标志物一致性分析：使用组织微阵列的回顾性研究。
Investig Clin Urol. 2020 Jul;61(4):372-381. doi: 10.4111/icu.2020.61.4.372. Epub 2020 May 25.
5
Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial.安罗替尼对比舒尼替尼作为转移性肾细胞癌一线治疗的随机 II 期临床试验。
Oncologist. 2019 Aug;24(8):e702-e708. doi: 10.1634/theoncologist.2018-0839. Epub 2019 Mar 22.
6
Liver metastasis and Heng risk are prognostic factors in patients with non-nephrectomized synchronous metastatic renal cell carcinoma treated with systemic therapy.肝转移和 Heng 风险是未行肾切除术的同步转移性肾细胞癌患者接受全身治疗的预后因素。
PLoS One. 2019 Feb 20;14(2):e0211105. doi: 10.1371/journal.pone.0211105. eCollection 2019.
7
A retrospective comparative study of progression-free survival and overall survival between metachronous and synchronous metastatic renal cell carcinoma in intermediate- or poor-risk patients treated with VEGF-targeted therapy.一项针对接受VEGF靶向治疗的中危或低危患者中异时性和同时性转移性肾细胞癌无进展生存期和总生存期的回顾性比较研究。
Oncotarget. 2017 Sep 6;8(55):93633-93643. doi: 10.18632/oncotarget.20674. eCollection 2017 Nov 7.
8
Evaluation of treatment response and resistance in metastatic renal cell cancer (mRCC) using integrated F-Fluorodeoxyglucose (F-FDG) positron emission tomography/magnetic resonance imaging (PET/MRI); The REMAP study.使用整合的F-氟脱氧葡萄糖（F-FDG）正电子发射断层扫描/磁共振成像（PET/MRI）评估转移性肾细胞癌（mRCC）的治疗反应和耐药性；REMAP研究。
BMC Cancer. 2017 Jun 2;17(1):392. doi: 10.1186/s12885-017-3371-9.
9
The epigenetic landscape of clear-cell renal cell carcinoma.透明细胞肾细胞癌的表观遗传格局
J Kidney Cancer VHL. 2015 May 28;2(3):90-104. doi: 10.15586/jkcvhl.2015.33. eCollection 2015.
10
A Prospective Multicenter Trial of the Efficacy and Tolerability of Neoadjuvant Sunitinib for Inoperable Metastatic Renal Cell Carcinoma.新辅助舒尼替尼治疗不可切除转移性肾细胞癌疗效和耐受性的前瞻性多中心试验
J Korean Med Sci. 2016 Dec;31(12):1983-1988. doi: 10.3346/jkms.2016.31.12.1983.
本文引用的文献
1
Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors.依维莫司治疗转移性肾细胞癌的 3 期临床试验：最终结果和预后因素分析。
Cancer. 2010 Sep 15;116(18):4256-65. doi: 10.1002/cncr.25219.
2
Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival.贝伐珠单抗联合干扰素 α-2a 治疗转移性肾细胞癌的 III 期临床试验（AVOREN）：总生存的最终分析。
J Clin Oncol. 2010 May 1;28(13):2144-50. doi: 10.1200/JCO.2009.26.7849. Epub 2010 Apr 5.
3
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial.帕唑帕尼治疗局部晚期或转移性肾细胞癌：一项随机 III 期试验结果。
J Clin Oncol. 2010 Feb 20;28(6):1061-8. doi: 10.1200/JCO.2009.23.9764. Epub 2010 Jan 25.
4
Quality of life in patients with metastatic renal cell carcinoma: the importance of patient-reported outcomes.转移性肾细胞癌患者的生活质量：患者报告结局的重要性。
Cancer Treat Rev. 2009 Dec;35(8):733-7. doi: 10.1016/j.ctrv.2009.07.003. Epub 2009 Aug 21.
5
Toxicity associated with the long-term use of targeted therapies in patients with advanced renal cell carcinoma.晚期肾细胞癌患者长期使用靶向治疗相关的毒性。
Expert Rev Anticancer Ther. 2009 Jun;9(6):795-805. doi: 10.1586/era.09.29.
6
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.舒尼替尼与干扰素α治疗转移性肾细胞癌患者的总生存期及更新结果比较
J Clin Oncol. 2009 Aug 1;27(22):3584-90. doi: 10.1200/JCO.2008.20.1293. Epub 2009 Jun 1.
7
Renal cell carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up.肾细胞癌：ESMO关于诊断、治疗及随访的临床建议
Ann Oncol. 2009 May;20 Suppl 4:81-2. doi: 10.1093/annonc/mdp137.
8
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.索拉非尼治疗肾细胞癌：肾癌全球评估试验中III期治疗方案的最终疗效和安全性结果
J Clin Oncol. 2009 Jul 10;27(20):3312-8. doi: 10.1200/JCO.2008.19.5511. Epub 2009 May 18.
9
EORTC-GU group expert opinion on metastatic renal cell cancer.欧洲癌症研究与治疗组织泌尿生殖系统肿瘤组关于转移性肾细胞癌的专家意见
Eur J Cancer. 2009 Mar;45(5):765-73. doi: 10.1016/j.ejca.2008.12.010. Epub 2009 Jan 20.
10
Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies.肾癌细胞因子治疗时代（1989 - 2005年）接受治疗患者的癌症特异性生存结果：新兴靶向癌症治疗的基准。
Cancer. 2008 Nov 1;113(9):2457-63. doi: 10.1002/cncr.23851.
Zotero 插件